Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Deciphera Pharmaceuticals (DCPH)
NASDAQ:DCPH
RESEARCH TOOLSreports
Deciphera Pharmaceuticals (DCPH) Stock Price & Analysis
242 Followers
DCPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.90 - $25.55
Previous Close$25.45
Volume253.30K
Average Volume (3M)1.72M
Market Cap
$2.20B
Enterprise Value$1.92B
Total Cash (Recent Filing)$306.22M
Total Debt (Recent Filing)$25.88M
Price to Earnings (P/E)-11.5
Beta0.66
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding86,475,972
10 Day Avg. Volume2,012,935
30 Day Avg. Volume1,720,520
Standard Deviation0.20
R-Squared0.00269
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.27
Price to Sales (P/S)45.57
Price to Cash Flow (P/CF)-19.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.84
Enterprise Value/Gross Profit12.03
Enterprise Value/Ebitda141.34
Forecast
1Y Price Target
$24.55Price Target Upside-3.57% Downside
Rating ConsensusHold
Number of Analyst Covering9
Deciphera Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Approval And CommercializationDeciphera's promising drug candidate, Vimseltinib, is on track for regulatory submissions, boosting confidence in its future market success and potential revenue growth.
Financial PerformanceDeciphera's financial results for the third quarter exceeded expectations, indicating operational efficiency and potential for increased profitability moving forward.
Mergers And AcquisitionsThe acquisition of Deciphera by Ono Pharmaceutical is poised to significantly enhance shareholder value, as the offer represents a substantial premium over Deciphera's recent share price.
Bears Say
Company PartnershipsPotential failure of the Ono Pharma deal to close poses a significant risk.
Drug SafetyEmerging safety signals for vimseltinib could negatively impact the stock's valuation.
Financial PerformanceQinlock product sales were below consensus and displayed a decrease from the previous quarter's sales figures.
---
Ownership Overview
30.08% Insiders
10.94% Mutual Funds
43.11% Other Institutional Investors
15.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DCPH FAQ
What was Deciphera Pharmaceuticals’s price range in the past 12 months?
Deciphera Pharmaceuticals lowest stock price was $9.90 and its highest was $25.55 in the past 12 months.
What is Deciphera Pharmaceuticals’s market cap?
Currently, no data Available
When is Deciphera Pharmaceuticals’s upcoming earnings report date?
Deciphera Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Deciphera Pharmaceuticals’s earnings last quarter?
Deciphera Pharmaceuticals released its earnings results on May 01, 2024. The company reported -$0.516 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.015.
Is Deciphera Pharmaceuticals overvalued?
According to Wall Street analysts Deciphera Pharmaceuticals’s price is currently Overvalued.
Does Deciphera Pharmaceuticals pay dividends?
Deciphera Pharmaceuticals does not currently pay dividends.
What is Deciphera Pharmaceuticals’s EPS estimate?
Deciphera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Deciphera Pharmaceuticals have?
Deciphera Pharmaceuticals has 86,475,975 shares outstanding.
What happened to Deciphera Pharmaceuticals’s price movement after its last earnings report?
Deciphera Pharmaceuticals reported an EPS of -$0.516 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went up 0.356%.
Which hedge fund is a major shareholder of Deciphera Pharmaceuticals?
Among the largest hedge funds holding Deciphera Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Deciphera Pharmaceuticals’s shares valued at 93M.
---
Deciphera Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.55 (-3.57% Downside)
$24.55 (-3.57% Downside)
Blogger Sentiment
Bullish
DCPH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $158.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.6%
Last 30 Days ▼ 11.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.03%
12-Months-Change
Fundamentals
Return on Equity
-50.37%
Trailing 12-Months
Asset Growth
-23.33%
Trailing 12-Months
Company Description
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
---
DCPH Earnings Call
Q4 2024
0:00 / 0:00
---
DCPH Stock 12 Month Forecast
Average Price Target
$24.55
▼(-3.57% Downside)
Technical Analysis
Karyopharm Therapeutics
―
Sangamo Biosciences
―
Arrowhead Pharmaceuticals
―
Corbus Pharmaceuticals
―
Best Analysts Covering DCPH
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+27.12%
reiterated a buy rating 3 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +27.12% per trade.
---